F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice

被引:0
|
作者
Marie-Bernadette Assié
Laurent Bardin
Agnès Auclair
Nathalie Consul-Denjean
François Sautel
Ronan Depoortère
Adrian Newman-Tancredi
机构
[1] Centre de Recherche Pierre Fabre,
关键词
Antipsychotic; Mouse brain; F15063; Plasma levels; Apomorphine-induced climbing and sniffing; D2-like receptor occupancy;
D O I
暂无
中图分类号
学科分类号
摘要
F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine fumarate salt) is a novel potential antipsychotic with dopamine D2/D3 blocking properties and agonist activity at 5-HT1A and D4 receptors. The pertinent parameter for pharmacological activity of antipsychotics appears to be central D2-like receptor occupancy. However, its duration is not necessarily correlated with drug plasma levels, on which clinical dosing regimens are often based. Thus, we compared in mice the duration of actions of F15063 and haloperidol to (1) inhibit apomorphine-induced climbing and sniffing (behavioural measures of D2-like receptor antagonism) and (2) occupy D2-like receptors in vivo in the striatum and olfactory tubercles (inhibition of [3H]nemonapride binding). Finally, we measured plasma levels of F15063. D2-like receptor occupancy in the striatum remained elevated at 1, 4 and 8 h postadministration, with both F15063 (ID50: 7.1, 3.6 and 16.5 mg/kg p.o., respectively) and the typical antipsychotic, haloperidol (ID50: 1.4, 0.52 and 0.53 mg/kg p.o., respectively). This was paralleled by a protracted inhibition of apomorphine-induced climbing (ED50: 0.9, 2.8 and 3.6 mg/kg p.o., and 0.21, 0.37 and 0.87 mg/kg p.o., respectively, for F15063 and haloperidol). In contrast, after administration of 10 mg/kg p.o. of F15063, its plasma levels decreased rapidly: 15.2, 2.1 and 0.6 ng/ml, 1, 4 and 8 h after administration, respectively. A similar pattern of results was observed when F15063 and haloperidol were administered i.p. and s.c., respectively. To summarise, the time-course of D2-like receptor occupancy and inhibition of apomorphine-climbing (and sniffing) behaviours was similarly long lasting with F15063 and haloperidol. In addition, the durations of action of F15063 and haloperidol in a behavioural model of antipsychotic-like activity were closely correlated to their occupancy of central D2-like receptors, and much longer than their presence in plasma.
引用
收藏
页码:241 / 250
页数:9
相关论文
共 50 条
  • [1] F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice
    Assie, Marie-Bernadette
    Bardin, Laurent
    Auclair, Agnes
    Consul-Denjean, Nathalie
    Sautel, Francois
    Depoortere, Ronan
    Newman-Tancredi, Adrian
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2007, 375 (04) : 241 - 250
  • [2] F15063, a novel antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: III.: Duration of brain D2-like receptor occupancy, antipsychotic-like activity and plasma concentration in rodents
    Assie, M. B.
    Bardin, L.
    Auclair, A. L.
    Consul-Denjean, N.
    Sautel, E.
    Kleven, M. S.
    Depoortere, R.
    Newman-Tancredi, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S432 - S433
  • [3] F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: Influence on neuronal firing and neurotransmitter release
    Assie, Marie-Bernadette
    Mnie-Filali, Ouissame
    Ravailhe, Veronique
    Benas, Christelle
    Marien, Marc
    Betry, Cecile
    Zimmer, Luc
    Haddjeri, Nasser
    Newman-Tancredi, Adrian
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 607 (1-3) : 74 - 83
  • [4] F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: (I) in vitro receptor affinity and efficacy profile
    Newman-Tancredi, A.
    Assie, M-B
    Martel, J-C
    Cosi, C.
    Slot, L. Bruins
    Palmier, C.
    Rauly-Lestienne, I.
    Colpaert, F.
    Vacher, B.
    Cussac, D.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (02) : 237 - 252
  • [5] F15063, an innovative antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: (I) in vitro, neurochemical and neuroendocrine profiles
    Newman-Tancredi, A.
    Assie, M. B.
    Martel, J. C.
    Cosi, C.
    Heusler, P.
    Slot, L. Bruins
    Carilla-Durand, E.
    Cussac, D.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S144 - S145
  • [6] F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: (II) Activity in models of positive symptoms of schizophrenia
    Depoortere, R.
    Bardin, L.
    Auclair, A. L.
    Kleven, M. S.
    Prinssen, E.
    Colpaert, F.
    Vacher, B.
    Newman-Tancredi, A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (02) : 253 - 265
  • [7] F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: (III) Activity in models of cognition and negative symptoms
    Depoortere, R.
    Auclair, A. L.
    Bardin, L.
    Slot, L. Bruins
    Kleven, M. S.
    Colpaert, F.
    Vacher, B.
    Newman-Tancredi, A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (02) : 266 - 277
  • [8] F15063, a novel antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: I.: Receptor affinity and efficacy in vitro and activity in neurochemical and neuroendocrine tests in rodents
    Newman-Tancredi, A.
    Assie, M. B.
    Martel, J. C.
    Cosi, C.
    Heusler, P.
    Slot, L. Bruins
    Carilla-Durand, E.
    Cussac, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S431 - S431
  • [9] F15063, an innovative antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: (II) behavioural profile in models of positive, negative symptoms and cognitive deficits of schizophrenia
    Depoortere, R.
    Bardin, L.
    Auclair, A.
    Slot, L. Bruins
    Kleven, M.
    Newman-Tancredi, A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S145 - S145
  • [10] F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist and 5-HT1A receptor agonist properties: Influence on immediate-early gene expression in rat prefrontal cortex and striatum
    Slot, Liesbeth A. Bruins
    Lestienne, Fabrice
    Grevoz-Barret, Catherine
    Newman-Tancredi, Adrian
    Cussac, Didier
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 620 (1-3) : 27 - 35